FDA Is Expected to Lift Restriction on Peptides, Heeding RFK Jr.'s Wishes The New York Times In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York The FDA has issued clear signals on BPC 157: it is not approved for human use in any form due to potential significant safety risks. This critical classification profoundly impacts research and FDA to weigh easing limits on peptides promoted by RFK Jr. NBC 6 South Florida